Cryolysate of Tumor Cells: From Technology of Its Obtaining up to Creation of Anti-сancer Vaccines
Keywords:
Ehrlich's ascites carcinoma, cryolysate, mononuclear cells, immune dendritic cells, culturingAbstract
The possibility of obtaining immune dendritic cells (iDCs) from bone marrow mononuclear cells has been proven by adding granulocyte-macrophage colony-stimulating factor, interleukin-4, and tumor cell cryolysate to the culture as an inducer of their maturation. The source of tumor antigens for obtaining iDCs was a cryolysate of Ehrlich adenocarcinoma cells, which was obtained by 5-fold freeze-thawing. It was established that the differentiation of mononuclear cells into iDCs is accompanied by the loss of the CD14 antigen, the appearance of maturity marker characteristics of these cells (CD83, CD11c antigens) and an increase in the expression of costimulatory molecules (CD80, CD86). The research results enable not only to evaluate the qualitative characteristics of iDCs obtained thereby, but also to outline the prospects of their use in immune correction of oncopathology.
Probl Cryobiol Cryomed 2024; 34(3):226–235
References
Alspach E, Lussier DM, Miceli AP, et al. MHC-II neoantigens shape tumour immunity and response to immunotherapy. Nature. 2019; 574(7780): 696-701. CrossRef
Bourque J, Hawiger D. Activation, amplification, and ablation as dynamic mechanisms of dendritic cell maturation. Biology (Basel). [Internet]. 2023 May 14 [Cited 20.05.2024]; 12(5): 716. Available from: https://www.mdpi.com/2079-7737/12/5/716 CrossRef
Cao WJ, Dai JY, Dong WJ, et al. [Effects of Dasatinib on the maturation of monocyte-derived dendritic cells derived from healthy donors and chronic myelogenous leukemia patients]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2022; 30(3): 677-687. Chinese. CrossRef
Date I, Koya T, Sakamoto T, et al. Interferon-α-induced dendritic cells generated with human platelet lysate exhibit elevated antigen presenting ability to cytotoxic T lymphocytes. Vaccines (Basel) [Internet]. 2020 Dec 24 [Cited 20.05.2024]; 9(1): 10. Available from: https://www.mdpi.com/2076-393X/9/1/10 CrossRef
Dillman RO, Cornforth AN, McClay EF, Depriest C. Patient-specific dendritic cell vaccines with autologous tumor antigens in 72 patients with metastatic melanoma. Melanoma Manag [Internet]. 2019 May 31 [Cited 20.05.2024]; 6(2): MMT20. Available from: https://www.futuremedicine.com/doi/full/10.2217/mmt-2018-0010 CrossRef
Dorrie J, Schaft N, Schuler G, Schuler-Thurner B. Therapeutic cancer vaccination with ex vivo rna-transfected dendritic cells-an update. Pharmaceutics [Internet]. 2020 Jan 23 [Cited 20.05.2024]; 12(2): 92. Available from: https://www.mdpi.com/1999-4923/12/2/92 CrossRef
Gardner A, de Mingo Pulido Á, Ruffell B. Dendritic cells and their role in immunotherapy. Front Immunol [Internet]. 2020 May 21 [Cited 20.05.2024]; 11: 924. Available from: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.00924/full CrossRef
Goltsev AN, Dubrava TG, Yampolskaya EE, et al. [The optimization method of isolation of immature dendritic cells]. Fiziol. Zh. 2018; (6): 33-40. Ukrainian. CrossRef
Jarnjak-Jankovic S, Pettersen RD, Saebøe-Larssen S, et al. Preclinical evaluation of autologous dendritic cells transfected with mRNA or loaded with apoptotic cells for immunotherapy of high-risk neuroblastoma. Cancer Gene Ther. 2005; 12(8): 699-707. CrossRef
Obermaier B, Dauer M, Herten J, et al. Development of a new protocol for 2-day generation of mature dendritic cells from human monocytes. Biol Proced Online. 2003; 5: 197-203. CrossRef
Perez CR, De Palma M. Engineering dendritic cell vaccines to improve cancer immunotherapy. Nat Commun [Internet]. 2019 Nov 27 [Cited 20.05.2024]; 10(1): 5408. Available from: https://www.nature.com/articles/s41467-019-13368-y CrossRef
Rapp M, Grauer OM, Kamp M, et al. A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial. Trials [Internet]. 2018 May 25 [Cited 20.05.2024]; 19(1): 293. Available from: https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-018-2659-7 CrossRef
Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med. 1994; 179(4): 1109-18.
Sorg RV, Ozcan Z, Brefort T, et al. Clinical-scale generation of dendritic cells in a closed system. J Immunother. 2003; 26(4): 374-83. CrossRef
Sugiura D, Maruhashi T, Okazaki IM, et al. Restriction of PD-1 function by cis-PD-L1/CD80 interactions is required for optimal T cell responses. Science. 2019; 364(6440): 558-66. CrossRef
Sutherland SIM, Ju X, Horvath LG, Clark GJ. Moving on from Sipuleucel-T: new dendritic cell vaccine strategies for prostate cancer. Front Immunol [Internet]. 2021 Mar 29 [Cited 20.05.2024]; 12: 641307. Available from: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.641307/full CrossRef
Ueno H, Klechevsky E, Morita R, et al. Dendritic cell subsets in health and disease. Immunol Rev. 2007; 219: 118-42. doi: 10.1111/j.1600-065X.2007.00551.x CrossRef
Van Tendeloo VF, Ponsaerts P, Lardon F, et al. Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood. 2001; 98(1): 49 -56. CrossRef
Wang Y, Xiang Y, Xin VW, et al. Dendritic cell biology and its role in tumor immunotherapy. J Hematol Oncol [Internet]. 2020 Aug 3 [Cited 20.05.2024]; 13(1): 107. Available from: https://jhoonline.biomedcentral.com/articles/10.1186/s13045-020-00939-6 CrossRef
Wculek SK, Cueto FJ, Mujal AM, et al. Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2020; 20(1): 7-24. CrossRef
Westdorp H, Creemers JHA, van Oort IM, et al. Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer. J Immunother Cancer [Internet]. 2019 Nov 14 [Cited 20.05.2024]; 7(1): 302. Available from: https://jitc.bmj.com/content/7/1/302.long CrossRef
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
